Zentek Ltd. announced the start of research coverage by Atrium Research and received its first orders under a Canadian government standing offer for its ZenGUARD™ air filters. The company also reported successful bench-scale purification of Albany graphite, achieving ultra-high purity levels up to 99.99985% carbon, supporting its Preliminary Economic Assessment. These developments position Zentek to supply high-spec graphite products for nuclear and defense markets and expand its government contracts. The technical report for the graphite project will be filed soon, with further progress updates expected.
More News
Ibezapolstat shows superior effectiveness against C. difficile and resistant Enterococcus in new study
Acurx Pharmaceuticals presented a study showing ibezapolstat (IBZ) outperforms vancomycin and fidaxomicin in killing Clostridioides difficile and vancomycin-resistant Enterococcus (VRE) in lab tests. IBZ maintained strong bactericidal activity even i…
AI growth powers NVIDIA and Palantir, but NVIDIA leads in infrastructure while Palantir excels in software.
NVIDIA and Palantir both reported strong quarterly results, highlighting unstoppable AI growth. NVIDIA focuses on the physical infrastructure powering AI models, with revenue up 106% and a strong data center segment. Palantir excels in software that …
Intel posts strongest revenue growth in 15 years; shares up 318% but $150 target by 2027 remains challenging.
Intel reported its strongest revenue growth in over 15 years with Q2 2026 revenue hitting $16.128 billion, driven by a 59% surge in Data Center and AI revenue. Shares have tripled in the past year, rising 318%, but momentum is slowing due to ongoing …
Dutch Bros donates $1 per drink on Sept 18 to support local youth organizations.
On September 18, Dutch Bros and its Foundation will donate $1 from every drink sold to local youth organizations as part of their 20th annual Buck for Kids Day. This event supports nonprofits like Big Brothers Big Sisters and Make-A-Wish, aiming to e…
Rhelion’s Filament Health presents at FDA hearing on future therapeutic use of psychedelics.
Rhelion Life Sciences’ subsidiary Filament Health Corp. participated in the FDA public hearing on September 14, 2026, discussing the potential future therapeutic use of psychedelic drugs. Filament’s president, Sarit Hashkes, provided oral remarks hig…
